TapewireFind a company

person · Reporting owner

MacNaughtan Murray David

Disclosed activity across 1 company

Tapewire entity
151330
SEC CIK
0001744661

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Jaguar Health, Inc.

Report date February 21, 2020 · Filed February 27, 2020

Section 16 reporting ended · disclosed 2020-02-27. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 24, 2019 Filed Jul 26, 2019 16:55 UTC Jaguar Health, Inc. JAGX · Entity 8387 GrantStock Option (right to buy) · Derivative 121,573 $0.00 Strike: $1.73 $0.00
Disclosure

SEC source: 0001104659-19-042090 · a4.xml · derivative · entry 1

MacNaughtan Murray David · CIK 0001744661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,573

Underlying: Common Stock · 121,573 shares

Expires 2022-07-24

F1 · security: Granted pursuant to the issuer's 2014 Equity Incentive Plan.

F2 · date: The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and Karen S. Wright, the Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding following the issuer's underwritten public offering that closed on July 23, 2019. Mr. Bochnowski and Ms. Wright certified the exact number of option shares to be granted on July 24, 2019, such that the effective date of the option grant was July 24, 2019.

F3 · derivative.exercise_date: Vests in equal monthly installments beginning on July 24, 2019, with one month of options, or 3,377 options, vested as of the grant date based on the reporting person's number of years of service on the issuer's board of directors, such that the grant is vested in full on the 3-year anniversary of the grant date.

Read SEC document
July 11, 2018 Filed Jul 13, 2018 17:33 UTC Jaguar Health, Inc. JAGX · Entity 8387 GrantStock Option (right to buy) · Derivative 104,860 $0.00 Strike: $1.36 $0.00
Disclosure

SEC source: 0001104659-18-045067 · a4.xml · derivative · entry 1

MacNaughtan Murray David · CIK 0001744661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,860

Underlying: Common Stock · 104,860 shares

Expires 2028-07-11

F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan.

F2 · date: The option grant was approved by the Issuer's board of directors on July 11, 2018.

F3 · derivative.exercise_date: Vests in equal monthly installments, beginning on July 11, 2018, such that it is vested in full on the 3-year anniversary of the grant date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.